Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

This should go to every media outlet! Leronlima

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153771
(Total Views: 618)
Posted On: 05/25/2025 8:02:37 AM
Posted By: biloxiblues
This should go to every media outlet!

Leronlimab—Suppressed Potential or Missed Opportunity?

CytoDyn’s drug leronlimab met its primary endpoint in a pivotal Phase 3 HIV trial. During COVID-19, top physicians including Dr. Seethamraju (Montefiore) and Dr. Otto Yang (UCLA) obtained Emergency Use Authorizations from the FDA to treat critically ill patients. The outcomes were dramatic—some intubated and ECMO patients fully recovered, with results published in prestigious journals like The New England Journal of Medicine.

Despite a 33% mortality reduction in critical patients, the FDA confined its trial design to moderately ill individuals, where the primary endpoint was not met. Physicians repeatedly affirmed leronlimab’s safety and efficacy, yet no authorization was granted.

Instead, the DOJ prosecuted CytoDyn’s CEO and CRO CEO. Both were acquitted of the central conspiracy charge, but convicted on lesser counts—despite rejecting plea deals that would’ve dropped most charges.

Subpoenaed FDA internal communications revealed:

A top FDA official saying, “I’m not going to look at their data. I’ll just deny it.”

The Director of Antiviral Products asking: “Why is this drug working?”

The FDA’s BLA review chief confirming CytoDyn’s application was reviewable—contrary to DOJ claims.


The leronlimab story represents a regulatory paradox: clinical promise overshadowed by political pressure and bureaucratic bias. With new leadership or partnerships, this drug’s future could still be lucrative—for patients and shareholders.



(15)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us